{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:27Z","timestamp":1791389127267,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["Bristol-Myers Squibb"],"award-info":[{"award-number":["Bristol-Myers Squibb"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10198-025-01808-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:20:19Z","timestamp":1750656019000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective"],"prefix":"10.1007","volume":"27","author":[{"given":"Francois-Emery","family":"Cott\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Akarkoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6325-5787","authenticated-orcid":false,"given":"Lou","family":"Chambry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Leproust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"1808_CR1","unstructured":"2023 ESC Guidelines for the management of cardiomyopathies| European Heart Journal:| Oxford Academic n.d. (2024). https:\/\/academic.oup.com\/eurheartj\/article\/44\/37\/3503\/7246608?login=false"},{"key":"1808_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.cir.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T., Bild, D.E.: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (Young). Adults Circulation. 92, 785\u2013789 (1995). https:\/\/doi.org\/10.1161\/01.cir.92.4.785","journal-title":"Adults Circulation"},{"key":"1808_CR3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron, M.S., Olivotto, I., Zenovich, A.G., Link, M.S., Pandian, N.G., Kuvin, J.T., et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 114, 2232\u20132239 (2006). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.644682","journal-title":"Circulation"},{"key":"1808_CR4","unstructured":"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation n.d. (2024). https:\/\/www.uptodate.com\/contents\/hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation"},{"key":"1808_CR5","unstructured":"National Protocols for Diagnosis and Care - HCM: (2021). https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-10\/protocole_national_de_diagnostic_et_de_soins_cmh_cardiogen_n_mansencal_p_charron.pdf (accessed February 8, 2024)"},{"key":"1808_CR6","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen, S.R., Mital, S., Burke, M.A., Day, S.M., Deswal, A., Elliott, P., et al.: 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. J. Am. Coll. Cardiol. 76, e159\u2013240 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2020.08.045","journal-title":"J. Am. Coll. Cardiol."},{"key":"1808_CR7","doi-asserted-by":"crossref","unstructured":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy| European Heart Journal:| Oxford Academic n.d. (2022). https:\/\/academic.oup.com\/eurheartj\/article\/35\/39\/2733\/853385","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"1808_CR8","unstructured":"Transparency Committee opinion - ISORYTHM n.d: (2024). https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-18305_ISORYTHM_PIC_REEV_AvisDef_CT18305.pdf"},{"key":"1808_CR9","unstructured":"Transparency Committee opinion - RYTHMODAN n.d: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-18420_RYTHMODAN_PIC_REEV_AvisDef_CT16311&18420.pdf (2024). (accessed August 19"},{"key":"1808_CR10","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.acvd.2023.10.082","volume":"117","author":"P Charron","year":"2024","unstructured":"Charron, P., Zema, C., Cotte, F.-E., Herquelot, E., Krause, T., Dayde, F., et al.: Clinical burden of obstructive hypertrophic cardiomyopathy: Insights from a nationwide study in France. Arch. Cardiovasc. Dis. 117, S46 (2024). https:\/\/doi.org\/10.1016\/j.acvd.2023.10.082","journal-title":"Arch. Cardiovasc. Dis."},{"key":"1808_CR11","unstructured":"European Medicines Agency: Camzyos: EPAR - Product information 2023. (2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/camzyos-epar-product-information_en.pdf"},{"key":"1808_CR12","unstructured":"Transparency Committee opinion - CAMZYOS: (2023). https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-02\/camzyos_18102023_summary_ct20438.pdf (accessed January 3, 2024)"},{"key":"1808_CR13","unstructured":"A randomized, double blind, placebo controlled clinical study to evaluate mavacamten (MYK-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03470545"},{"key":"1808_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T.P., Masri, A., Garcia-Pavia, P., et al.: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 396, 759\u2013769 (2020). https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"key":"1808_CR15","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia, P., Or\u0119ziak, A., Masri, A., Barriales-Villa, R., Abraham, T.P., Owens, A.T., et al.: Long-term effect of Mavacamten in obstructive hypertrophic cardiomyopathy. Eur. Heart J. ehae579 (2024). https:\/\/doi.org\/10.1093\/eurheartj\/ehae579","DOI":"10.1093\/eurheartj\/ehae579"},{"key":"1808_CR16","unstructured":"Publishes evidence report on mavacamten for hypertrophic cardiomyopathy: ICER n.d. (2022). https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-evidence-report-on-mavacamten-for-hypertrophic-cardiomyopathy\/"},{"key":"1808_CR17","unstructured":"HAS - Methodological Guidance: - Choices in methods for economic evaluation 2020. (2024). https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf"},{"key":"1808_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","volume":"13","author":"LP Garrison","year":"2010","unstructured":"Garrison, L.P., Mansley, E.C., Abbott, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-Effectiveness analyses: A societal perspective: The ISPOR drug cost task force Report\u2014Part II. Value Health. 13, 8\u201313 (2010). https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00660.x","journal-title":"Value Health"},{"key":"1808_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1067\/mhl.2002.124554","volume":"31","author":"JA Bennett","year":"2002","unstructured":"Bennett, J.A., Riegel, B., Bittner, V., Nichols, J.: Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung J. Crit. Care. 31, 262\u2013270 (2002). https:\/\/doi.org\/10.1067\/mhl.2002.124554","journal-title":"Heart Lung J. Crit. Care"},{"key":"1808_CR20","doi-asserted-by":"publisher","first-page":"e014240","DOI":"10.1161\/JAHA.119.014240","volume":"8","author":"C Caraballo","year":"2019","unstructured":"Caraballo, C., Desai, N.R., Mulder, H., Alhanti, B., Wilson, F.P., Fiuzat, M., et al.: Clinical implications of the new York heart association classification. J. Am. Heart Assoc. 8, e014240 (2019). https:\/\/doi.org\/10.1161\/JAHA.119.014240","journal-title":"J. Am. Heart Assoc."},{"key":"1808_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.acvd.2024.04.001","volume":"117","author":"A Parodi","year":"2024","unstructured":"Parodi, A., Puscas, T., R\u00e9ant, P., Donal, E., M\u2019Barek Raboudi, D., Billon, C., et al.: Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life Estimation from the French register of hypertrophic cardiomyopathy (REMY). Arch. Cardiovasc. Dis. 117, 427\u2013432 (2024). https:\/\/doi.org\/10.1016\/j.acvd.2024.04.001","journal-title":"Arch. Cardiovasc. Dis."},{"key":"1808_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40273-018-0755-x","volume":"37","author":"GL Di Tanna","year":"2019","unstructured":"Di Tanna, G.L., Bychenkova, A., O\u2019Neill, F., Wirtz, H.S., Miller, P., Hartaigh, \u00d3.: Evaluating Cost-Effectiveness models for Pharmacologic interventions in adults with heart failure: A systematic literature. Rev. PharmacoEconomics. 37, 359\u2013389 (2019). https:\/\/doi.org\/10.1007\/s40273-018-0755-x","journal-title":"Rev. PharmacoEconomics"},{"key":"1808_CR23","unstructured":"Overview: accessed July 6,| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure| Guidance| NICE n.d. (2022). https:\/\/www.nice.org.uk\/guidance\/ta314"},{"key":"1808_CR24","unstructured":"Overview: accessed July 6,| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy| Guidance| NICE n.d. (2022). https:\/\/www.nice.org.uk\/guidance\/ta696"},{"key":"1808_CR25","unstructured":"CEESP economic opinion - VYNDAQEL: (2020). https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-12\/vyndaqel_17112020_avis_economique.pdf (accessed August 19, 2024)"},{"key":"1808_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","volume":"44","author":"N Desai","year":"2022","unstructured":"Desai, N., Xie, J., Wang, Y., Sutton, M.B., Whang, J., Fine, J.T., et al.: Projecting the Long-term clinical value of Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the united states: An assessment of net health benefit. Clin. Ther. 44, 52\u201366e2 (2022). https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.006","journal-title":"Clin. Ther."},{"key":"1808_CR27","unstructured":"NICE. Single Technology Appraisal: - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928] - Committee Papers 2022. (2024). https:\/\/www.nice.org.uk\/guidance\/ta913\/evidence\/committee-papers-pdf-13133205181"},{"key":"1808_CR28","unstructured":"Public Summary Document - November: 2023 PBAC Meeting - Mavacamten n.d. (2024). https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2023-11\/files\/mavacamten-psd-nov-2023.pdf"},{"key":"1808_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00392-020-01797-5","volume":"111","author":"M Hourqueig","year":"2022","unstructured":"Hourqueig, M., Bouzille, G., Mirabel, M., Huttin, O., Damy, T., Labombarda, F., et al.: Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: A clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY). Clin. Res. Cardiol. Off J. Ger. Card Soc. 111, 163\u2013174 (2022). https:\/\/doi.org\/10.1007\/s00392-020-01797-5","journal-title":"Clin. Res. Cardiol. Off J. Ger. Card Soc."},{"key":"1808_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamacardio.2019.4534","volume":"5","author":"M Lorenzini","year":"2020","unstructured":"Lorenzini, M., Anastasiou, Z., O\u2019Mahony, C., Guttman, O.P., Gimeno, J.R., Monserrat, L., et al.: Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol. 5, 73\u201380 (2020). https:\/\/doi.org\/10.1001\/jamacardio.2019.4534","journal-title":"JAMA Cardiol."},{"key":"1808_CR31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho, C.Y., Day, S.M., Ashley, E.A., Michels, M., Pereira, A.C., Jacoby, D., et al.: Genotype and lifetime burden of disease in hypertrophic cardiomyopathy. Circulation. 138, 1387\u20131398 (2018). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200","journal-title":"Circulation"},{"key":"1808_CR32","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/13696998.2023.2277076","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Gao, W., Han, X., Jiang, J., Sandler, B., Li, X., et al.: Cardiovascular outcomes by time-varying new York heart association class among patients with obstructive hypertrophic cardiomyopathy: A retrospective cohort study. J. Med. Econ. 26, 1495\u20131506 (2023). https:\/\/doi.org\/10.1080\/13696998.2023.2277076","journal-title":"J. Med. Econ."},{"key":"1808_CR33","unstructured":"INSEE \u2013\u20092022 Demographic review: (2022). (accessed February 8, 2024) https:\/\/www.insee.fr\/fr\/statistiques\/6686511?sommaire=6686521"},{"key":"1808_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","volume":"38","author":"LF Andrade","year":"2020","unstructured":"Andrade, L.F., Ludwig, K., Goni, J.M.R., Oppe, M., de Pouvourville, G.: A French value set for the EQ-5D-5L. PharmacoEconomics. 38, 413\u2013425 (2020). https:\/\/doi.org\/10.1007\/s40273-019-00876-4","journal-title":"PharmacoEconomics"},{"key":"1808_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01559-2","author":"L Gautier","year":"2023","unstructured":"Gautier, L., Azzi, J., Saba, G., Bonnelye, G., de Pouvourville, G.: Population norms in France with EQ-5D-5L: Health states, value indexes, and VAS. Eur. J. Health Econ. (2023). https:\/\/doi.org\/10.1007\/s10198-022-01559-2","journal-title":"Eur. J. Health Econ."},{"key":"1808_CR36","unstructured":"French National Insurance - published price database: n.d. (2024). http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index_presentation.php?p_site=AMELI"},{"key":"1808_CR37","unstructured":"CCAM en ligne - CCAM n.d: (2024). https:\/\/www.ameli.fr\/accueil-de-la-ccam\/index.php"},{"key":"1808_CR38","unstructured":"ameli, le site de l\u2019Assurance Maladie en ligne| ameli.fr| Assur\u00e9 n.d. (2024). https:\/\/www.ameli.fr\/assure"},{"key":"1808_CR39","unstructured":"DGOS: Le r\u00e9f\u00e9rentiel des actes innovants hors nomenclature de biologie et d\u2019anatomopathologie (RIHN). Minist\u00e8re Sant\u00e9 Pr\u00e9v 2023. (2023). https:\/\/sante.gouv.fr\/systeme-de-sante\/innovation-et-recherche\/rihn"},{"key":"1808_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","volume":"102","author":"G Mickisch","year":"2010","unstructured":"Mickisch, G., Gore, M., Escudier, B., Procopio, G., Walzer, S., Nuijten, M.: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-\u03b12a compared with Sunitinib. Br. J. Cancer. 102, 80\u201386 (2010). https:\/\/doi.org\/10.1038\/sj.bjc.6605417","journal-title":"Br. J. Cancer"},{"key":"1808_CR41","unstructured":"ATIH\u2019s ScanSant\u00e9 n.d. Diagnosis-related group: (2024)"},{"key":"1808_CR42","unstructured":"Cour des Comptes. LES, TRANSPORTS PROGRAMM\u00c9S DANS LES SECTEURS SANITAIRE ET, M\u00c9DICOSOCIAL: DES ENJEUX \u00c0 MIEUX RECONNA\u00ceTRE, UNE R\u00c9GULATION \u00c0 RECONSTRUIRE: (2019). https:\/\/www.ccomptes.fr\/system\/files\/2019-10\/RALFSS-2019-06-transports-programmes-secteurs-sanitaire-medicosocial.pdf (accessed August 19, 2024)"},{"key":"1808_CR43","unstructured":"Regional gross domestic product: from 2000 to 2020 - Insee n.d. (2024). https:\/\/www.insee.fr\/fr\/statistiques\/6440639#tableau-figure2"},{"key":"1808_CR44","unstructured":"GVS report mavacamten (Camzyos\u00ae): - Zorginstituut Netherlands n.d. (2024). https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/adviezen\/2024\/05\/01\/gvs-advies-mavacamten-camzyos-bij-hocm\/Advies+-+vergoed+mavacamten+%28Camzyos%C2%AE%29+voor+de+behandeling+van+een+bepaalde+hartspierziekte.pdf"},{"key":"1808_CR45","unstructured":"CEESP economic opinion - CAMZYOS: (2024). https:\/\/sci-hub.scrongyao.com\/10.1007\/s12325-021-01767-x (accessed August 1, 2024)"},{"key":"1808_CR46","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40273-024-01393-9","volume":"42","author":"S Ghabri","year":"2024","unstructured":"Ghabri, S.: Could or should we use Cost-Effectiveness thresholds in the French Value-Based pricing process for new drugs?? PharmacoEconomics. 42, 823\u2013827 (2024). https:\/\/doi.org\/10.1007\/s40273-024-01393-9","journal-title":"PharmacoEconomics"},{"key":"1808_CR47","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jval.2020.04.001","volume":"23","author":"B T\u00e9hard","year":"2020","unstructured":"T\u00e9hard, B., Detournay, B., Borget, I., Roze, S., De Pouvourville, G.: Value of a QALY for france: A new approach to propose acceptable reference values. Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res. 23, 985\u2013993 (2020). https:\/\/doi.org\/10.1016\/j.jval.2020.04.001","journal-title":"Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"1808_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/scs.13006","volume":"36","author":"M Mortensen","year":"2022","unstructured":"Mortensen, M., Sandvik, R.K.N.M., Svendsen, \u00d8.S., Haaverstad, R., Moi, A.L.: Return to work after coronary artery bypass grafting and aortic valve replacement surgery: A scoping review. Scand. J. Caring Sci. 36, 893\u2013909 (2022). https:\/\/doi.org\/10.1111\/scs.13006","journal-title":"Scand. J. Caring Sci."},{"key":"1808_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3111\/13696998.2014.923891","volume":"17","author":"T Lanitis","year":"2014","unstructured":"Lanitis, T., Cott\u00e9, F.E., Gaudin, A.F., Kachaner, I., Kongnakorn, T., Durand-Zaleski, I.: Stroke prevention in patients with atrial fibrillation in france: Comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J. Med. Econ. 17, 587\u2013598 (2014). https:\/\/doi.org\/10.3111\/13696998.2014.923891","journal-title":"J. Med. Econ."},{"key":"1808_CR50","unstructured":"CEA Registry - Center for the Evaluation of Value: and Risk in Health n.d. (2023). https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry"},{"key":"1808_CR51","unstructured":"Journal Officiel: Mavacamten published list price n.d. (2024). https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000049951158"},{"key":"1808_CR52","unstructured":"Summary of Product Characteristics - NADOLOL n.d: (2024). https:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0213569.htm"},{"key":"1808_CR53","unstructured":"Summary of Product Characteristics - PINDOLOL n.d: (2024). https:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0166522.htm"},{"key":"1808_CR54","unstructured":"Summary of Product Characteristics - PROPRANOLOL n.d: (2024). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190111143237\/anx_143237_en.pdf"},{"key":"1808_CR55","unstructured":"Summary of Product Characteristics - VERAPAMIL n.d: (2024). https:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0236363.htm"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01808-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:04:26Z","timestamp":1771862666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01808-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01808-0","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cott\u00e9 FE, Hurst M, and Vernon J are employees of BMS. Akarkoub S, Chambry L, and Leproust S are employees of IQVIA who worked on behalf of BMS to conduct this study. Ho M is employee of Open Health Group who worked on behalf of BMS to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}